Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial

Martinez, Juana; Subramanian, Kritika; Castellanos, Sandra Huicochea; Thomas, Charlene; Choudhury, Arindam Roy; Muench, Brett; Tagawa, Scott T.; Pillarsetty, Naga Vara Kishore; Osborne, Joseph R.

doi:10.1016/j.tranon.2022.101593

Cited by 4 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Work on direct cyclotron production of 68 Ga via solid or liquid 68 Zn enriched targets 10 is ongoing which, if successful, may offset some of the disadvantages in its current pathway and facilitate improved scalability. Preliminary studies have shown safety 11 and favourable levels of agreement compared with generator-produced equivalents, 12 although larger trials including cost-benefit analyses are needed before widespread clinical application.…”

Section: Psma Radioligandsmentioning

confidence: 99%

Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands

Naik,

Khan,

Lewington

et al. 2024

British Journal of Radiology

View full text Add to dashboard Cite

Prostate specific membrane antigen (PSMA)-directed PET imaging has rapidly transformed prostate cancer workup over the past decade and paved the way for a theranostic approach using 177Lu-labelled PSMA radioligand therapy. This review gives an overview of the underlying principles behind PSMA as a target; the current use of PSMA PET in prostate cancer imaging and benefits compared to conventional imaging; and therapeutic applications including optimisation of patient selection. It also explores the evidence base of PSMA PET for other indications not in routine clinical use and the future of PSMA-directed radioligand therapy.

show abstract

Section: Psma Radioligandsmentioning

confidence: 99%